The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Jerez, Andrés (Vall d'Hebron Institut d'Oncologia)
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)

Date:	2023
Abstract:	There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. However, since these risk factors are not exclusive for secondary MDSs and there are multiple overlapping scenarios, a comprehensive and definitive classification is yet to come. In addition, a sporadic MDS might arise after a primary tumor fulfills the diagnostic criteria of MDS-pCT without a causative cytotoxicity. In this review, we describe the triggering pieces of a secondary MDS jigsaw: previous cytotoxic therapy, germline predisposition and clonal hematopoiesis. Epidemiological and translational efforts are needed to put these pieces together and ascertain the real weight of each of these pieces in each MDS patient. Future classifications must contribute to understanding the role of secondary MDS jigsaw pieces in different concomitant or independent clinical scenarios associated with the primary tumor.
Grants:	Instituto de Salud Carlos III PI20/00531 Instituto de Salud Carlos III PI/17/0575 Instituto de Salud Carlos III PI19/00374 Instituto de Salud Carlos III PI22/00102 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR00560 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR288
Note:	This research was funded by the Instituto de Salud Carlos III, Ministerio de Economia y Competividad, grant numbers PI/17/0575, PI19/00374, PI 20/00531 and PI22/00102; TRANSCAN, grant numbers AECC AC 18/000002 and ISCIII; and Generalitat de Catalunya, grant numbers 2017 SGR288 (GRC) and SGR00560 (GRC).
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Subject:	Myelodysplastic neoplasms (MDSs) ; Secondary MDS ; Genetic predisposition ; Therapy-related myeloid neoplasm (TRMN) ; MDS post-cytotoxic therapy (MDS-pCT) ; MDS comorbidity ; Clonal hematopoiesis of indeterminate potential (CHIP)
Published in:	Cancers, Vol. 15 Núm. 5 (march 2023) , p. 1483, ISSN 2072-6694

DOI: 10.3390/cancers15051483
PMID: 36900275

12 p, 801.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles
Articles > Reviews